{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05391126",
            "orgStudyIdInfo": {
                "id": "MCC-22-GI-125-PMC"
            },
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care",
            "officialTitle": "GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "genocare-a-prospective-randomized-clinical-trial-of-genotype-guided-dosing-versus-usual-care"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-20",
            "studyFirstSubmitQcDate": "2022-05-20",
            "studyFirstPostDateStruct": {
                "date": "2022-05-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-06",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Reema A. Patel",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Reema A. Patel",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (\\*1/\\*28) (heterozygotes) and usual UGT metabolizers (\\*1/\\*1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual UGT1A1 genotypes (\\*1/\\*28, \\*1/\\*1) will be randomized to genotype-guided dosing versus usual care."
        },
        "conditionsModule": {
            "conditions": [
                "Colorectal Cancer",
                "Pancreatic Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 178,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Genocare Guided",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Irinotecan"
                    ]
                },
                {
                    "label": "Usual Care",
                    "type": "NO_INTERVENTION"
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Irinotecan",
                    "description": "Usual dosing per package insert.",
                    "armGroupLabels": [
                        "Genocare Guided"
                    ],
                    "otherNames": [
                        "Nano-liposomal Irinotecan",
                        "Onyvide"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events Frequency",
                    "description": "To compare the frequency of cycle 1 grade 3-5 adverse effects in individuals with a \\*1/\\*28 or \\*1/\\*1 genotype who receive genotype-guided dosing and to those who are randomized to receive usual care.",
                    "timeFrame": "6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Survival",
                    "description": "To evaluate overall survival between individuals randomized to receive genotype-guided dosing and those who are randomized to receive usual care.",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically confirmed stage I-IV pancreas or stage III-IV colorectal cancer who are planning to undergo treatment.\n* Prior treatment is allowed, specifically surgery and/or radiation and non-irinotecan containing regimens are allowed.\n* Age \u2265 18 years.\n* ECOG performance status \u2264 1.\n* Patients must have adequate organ and marrow function as defined below:\n* Measurable or non-measurable disease.\n\nExclusion Criteria:\n\n* Patients who received prior treatment with irinotecan are excluded.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.\n* Pregnant women are excluded from this study.\n* Patients who are not planned for treatment of their cancer.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reema A Patel, MD",
                    "role": "CONTACT",
                    "phone": "8592186650",
                    "email": "reema.patel@uky.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Reema A Patel, MD",
                    "affiliation": "University of Kentucky",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kentucky",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40506",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yvonne Taul",
                            "role": "CONTACT",
                            "phone": "859-323-2354",
                            "email": "Yvonne.Taul@uky.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077146",
                    "term": "Irinotecan"
                }
            ],
            "ancestors": [
                {
                    "id": "D000059004",
                    "term": "Topoisomerase I Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "asFound": "Related",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29349",
                    "name": "Topoisomerase I Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}